MRT-199665 is developed as an effective, ATP competitive, selective MARK/SIK/AMPK inhibitor.8 MRT-199665 inhibits SIK-mediated CRTC3 phosphorylation to increase LPS-stimulated IL-10 production and inhibit the secretion of proinflammatory cytokines, such as IL-6, IL-12, and TNFα in macrophages.8,85 MRT-199665 can also induce apoptosis of human acute myeloid leukemia cells by activating MEF2C in vitro,157 and enhance TGF-β-mediated apoptosis and death of murine mammary epithelial cells.85 YKL-06-061 and YKL-06-062 are employed as selective second-generation inhibitors of SIKs. This evidence concerns the gene SIK1 and acute myeloid leukemia.